Payment overview · 2025
General Payments
$357.29
17 reported records · 13 companies
Healthcare provider profile · identity verified
Miranda P Smith, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BOAZ, AL · NPI 1568702611
Verified facts
What the public records show
CMS Open Payments records show Miranda P Smith, CRNP received $357.29 in general payments during 2025 across 17 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $66.10 | 18.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.67 | 18.4% | 3 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $27.47 | 7.7% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $27.13 | 7.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.25 | 6.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.87 | 5.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.77 | 5.8% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $20.58 | 5.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.61 | 5.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.57 | 5.5% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.66 | 5.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.99 | 4.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.62 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $357.29 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $66.10 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $65.67 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.51 | 2 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $27.47 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.57 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 18 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 553 | 192 |
| Omeprazole | Omeprazole | 355 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 324 | 101 |
| Trazodone Hcl | Trazodone Hcl | 305 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 270 | 94 |
| Lisinopril | Lisinopril | 251 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 73 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 210 | 60 |
| Metformin Hcl | Metformin Hcl | 204 | 83 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 194 | 69 |
| Montelukast Sodium | Montelukast Sodium | 187 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 171 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 45 |
| Losartan Potassium | Losartan Potassium | 153 | 60 |
| Ezetimibe | Ezetimibe | 148 | 51 |
| Methocarbamol | Methocarbamol | 145 | 45 |
| Tizanidine Hcl | Tizanidine Hcl | 140 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 127 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 50 |
| Meloxicam | Meloxicam | 124 | 42 |
| Buspirone Hcl | Buspirone Hcl | 119 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 107 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 37 |
| Glipizide Er | Glipizide | 105 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 42 |
| Carvedilol | Carvedilol | 90 | 29 |
| Alendronate Sodium | Alendronate Sodium | 87 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 87 | 39 |
| Allopurinol | Allopurinol | 86 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 22 |
| Famotidine | Famotidine | 78 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 77 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 24 |
| Furosemide | Furosemide | 72 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 71 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 34 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 69 | 30 |
| Donepezil Hcl | Donepezil Hcl | 69 | 32 |
| Eliquis | Apixaban | 67 | 16 |
| Potassium Chloride | Potassium Chloride | 67 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 23 |
| Ozempic | Semaglutide | 63 | 21 |
| Simvastatin | Simvastatin | 63 | 26 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 61 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 16 |
| Linzess | Linaclotide | 57 | 18 |
| Amoxicillin | Amoxicillin | 55 | 47 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 18 |
| Sertraline Hcl | Sertraline Hcl | 53 | 14 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 52 | 41 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Prednisone | Prednisone | 51 | 50 |
| Celecoxib | Celecoxib | 50 | 21 |
| Glimepiride | Glimepiride | 50 | 18 |
| Fenofibrate | Fenofibrate | 49 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 24 |
| Doxepin Hcl | Doxepin Hcl | 46 | 17 |
| Topiramate | Topiramate | 46 | suppressed |
| Atenolol | Atenolol | 42 | 12 |
| Januvia | Sitagliptin Phosphate | 42 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 15 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | 11 |
| Meclizine Hcl | Meclizine Hcl | 38 | 17 |
| Mounjaro | Tirzepatide | 37 | 13 |
| Trulicity | Dulaglutide | 35 | 13 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | 15 |
| Gabapentin | Gabapentin | 30 | 16 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Etodolac | Etodolac | 27 | 11 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | 11 |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Primidone | Primidone | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 16 |
| Nystatin | Nystatin | 23 | 14 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 19 |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 18 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Tradjenta | Linagliptin | 18 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Bumetanide | Bumetanide | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Fosinopril-Hydrochlorothiazide | Fosinopril/Hydrochlorothiazide | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $357.29 · 17 records | Bayer Healthcare Pharmaceuticals Inc. | CAPLYTA, ELIQUIS, FANAPT, FREESTYLE LIBRE 3, IBSRELA, Kerendia, LifeVest, MOUNJARO, NURTEC ODT, QULIPTA, REXULTI, Tyvaso, UBRELVY, VOQUEZNA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error